Literature DB >> 11752132

Angiotensin peptides modulate bradykinin levels in the interstitium of the dog heart in vivo.

Chih-Chang Wei1, Carlos M Ferrario, K Bridget Brosnihan, Diane M Farrell, Wayne E Bradley, Ayad A Jaffa, Louis J Dell'Italia.   

Abstract

We previously demonstrated the substantial capacity for angiotensin (ANG) II formation in the interstitium of the dog heart in vivo. The current study tested the hypothesis that interstitial fluid (ISF) bradykinin (BK) is influenced by ANG II formation. Four microdialysis probes were inserted into the left ventricular myocardium of eight open-chest anesthetized dogs. The probe effluent was collected during four stages in each dog. Probes 1 and 3 sequentially delivered: 1) buffer; 2) ANG I (15 microM); 3) ANG II type 1 receptor antagonist (AT(1)-ant; irbesartan, 50 microM) or AT(2)-ant (PD123319, 50 microM); and 4) ANG I + AT(1)-ant or ANG I + AT(2)-ant. Probes 2 and 4 used the same protocol, substituting ANG II for ANG I in a concentration (0.5 microM) equivalent to that achieved during ANG I infusion. ISF BK levels increased 15-fold during ANG I (p < 0.001) but not during ANG II infusion. Co-infusion of selective AT(1)- and AT(2)-ants or nonselective AT-ant did not block the increase in ISF BK. ISF infusions of ANG I also produced a greater than 400-fold rise in ISF ANG-(1-7) over baseline. ISF infusion of ANG-(1-7) (10 microM) produced a 15-fold increase in ISF BK (p < 0.001). The metabolic machinery exists for the formation of BK and ANG-(1-7) in the cardiac ISF space that is not blocked by an AT receptor antagonist. The differential increase in ISF BK during ANG I and ANG-(1-7) but not during ANG II infusions suggests the possibility of decreased catabolism of ISF BK by an angiotensin-converting enzyme due to active site occupation by ANG I and ANG-(1-7).

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11752132     DOI: 10.1124/jpet.300.1.324

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  6 in total

1.  Angiotensin-(1-7) attenuates angiotensin II-induced cardiac remodeling associated with upregulation of dual-specificity phosphatase 1.

Authors:  Latronya T McCollum; Patricia E Gallagher; E Ann Tallant
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-12-02       Impact factor: 4.733

2.  The one-two punch: knocking out angiotensin II in the heart.

Authors:  Daniela Zablocki; Junichi Sadoshima
Journal:  J Clin Invest       Date:  2010-03-24       Impact factor: 14.808

Review 3.  Angiotensin-(1-7) as an antihypertensive, antifibrotic target.

Authors:  Michael J Katovich; Justin L Grobe; Mohan K Raizada
Journal:  Curr Hypertens Rep       Date:  2008-06       Impact factor: 5.369

4.  Increased myocardial stiffness due to cardiac titin isoform switching in a mouse model of volume overload limits eccentric remodeling.

Authors:  Kirk R Hutchinson; Chandra Saripalli; Charles S Chung; Henk Granzier
Journal:  J Mol Cell Cardiol       Date:  2014-11-08       Impact factor: 5.000

5.  Distinct roles for angiotensin-converting enzyme 2 and carboxypeptidase A in the processing of angiotensins within the murine heart.

Authors:  Paul J Garabelli; J Gregory Modrall; Josef M Penninger; Carlos M Ferrario; Mark C Chappell
Journal:  Exp Physiol       Date:  2008-03-20       Impact factor: 2.969

Review 6.  Advances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1-7) in regulation of cardiovascular function.

Authors:  Carlos M Ferrario; Aaron J Trask; Jewell A Jessup
Journal:  Am J Physiol Heart Circ Physiol       Date:  2005-07-29       Impact factor: 4.733

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.